These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17266582)

  • 1. Virostatics: a new class of anti-HIV drugs.
    Lori F; Foli A; Kelly LM; Lisziewicz J
    Curr Med Chem; 2007; 14(2):233-41. PubMed ID: 17266582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms.
    Lori F; Foli A; Groff A; Lova L; Whitman L; Bakare N; Pollard RB; Lisziewicz J
    AIDS; 2005 Jul; 19(11):1173-81. PubMed ID: 15990570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Virostatics" as a potential new class of HIV drugs.
    Kelly LM; Lisziewicz J; Lori F
    Curr Pharm Des; 2004; 10(32):4103-20. PubMed ID: 15579091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.
    Lisziewicz J; Foli A; Wainberg M; Lori F
    Drug Saf; 2003; 26(9):605-24. PubMed ID: 12814330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of hydroxyurea in the treatment of HIV infection.
    Lori F; Kelly LM; Foli A; Lisziewicz J
    Expert Opin Drug Saf; 2004 Jul; 3(4):279-88. PubMed ID: 15268646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
    Lori F; Lisziewicz J
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S193-7. PubMed ID: 10860905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea.
    Boelaert JR; Sperber K; Piette J
    AIDS Res Hum Retroviruses; 1999 Sep; 15(14):1241-7. PubMed ID: 10505672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411.
    Uglietti A; Maserati R
    Expert Opin Investig Drugs; 2011 Apr; 20(4):559-65. PubMed ID: 21391888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
    Lori F; Rosenberg E; Lieberman J; Foli A; Maserati R; Seminari E; Alberici F; Walker B; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 Oct; 15(15):1333-8. PubMed ID: 10515148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
    Clotet B; Ruiz L; Cabrera C; Ibáñez A; Cañadas MP; Sirera G; Romeu J; Vila J
    Antivir Ther; 1996 Aug; 1(3):189-93. PubMed ID: 11322253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
    Lori F; Pollard RB; Whitman L; Bakare N; Blick G; Shalit P; Foli A; Peterson D; Tennenberg A; Schrader S; Rashbaum B; Farthing C; Herman D; Norris D; Greiger P; Frank I; Groff A; Lova L; Asmuth D; Lisziewicz J
    AIDS Res Hum Retroviruses; 2005 Apr; 21(4):263-72. PubMed ID: 15943568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of human immunodeficiency virus type 1 inhibition by hydroxyurea.
    Lori F; Lisziewicz J
    J Biol Regul Homeost Agents; 1999; 13(3):176-80. PubMed ID: 10560752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.
    Lori F; Malykh AG; Foli A; Maserati R; De Antoni A; Minoli L; Padrini D; Degli Antoni A; Barchi E; Jessen H; Wainberg MA; Gallo RC; Lisziewicz J
    AIDS Res Hum Retroviruses; 1997 Nov; 13(16):1403-9. PubMed ID: 9359660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea.
    López M; Benito JM; Lozano S; Barreiro P; Martínez P; González-Lahoz J; Soriano V
    AIDS; 2004 Jun; 18(9):1251-61. PubMed ID: 15362657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea in HIV therapy.
    HIV Hotline; 1998 Mar; 8(1):5-7. PubMed ID: 11365359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea, a potential new anti-HIV agent.
    Torres G
    GMHC Treat Issues; 1995 Jan; 9(1):7-9. PubMed ID: 11367381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir).
    Lori F; Jessen H; Lieberman J; Clerici M; Tinelli C; Lisziewicz J
    AIDS Res Hum Retroviruses; 1999 May; 15(7):619-24. PubMed ID: 10331440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease.
    Perry CM; Balfour JA
    Drugs; 1996 Dec; 52(6):928-62. PubMed ID: 8957161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.
    Lori F; Malykh A; Cara A; Sun D; Weinstein JN; Lisziewicz J; Gallo RC
    Science; 1994 Nov; 266(5186):801-5. PubMed ID: 7973634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.